NCT06622109View on ClinicalTrials.gov

A Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six Months

Active, not recruitingOBSERVATIONAL

Enrollment

1,100

Participants

Timeline

Start Date

November 25, 2024

Primary Completion Date

January 15, 2027

Study Completion Date

January 15, 2027

Conditions

Pneumococcal Disease

Interventions

BIOLOGICAL

20-valent Pneumococcal Conjugate Vaccine

Injection in the muscle or subcutaneous , 1 dose 0.5mL

Trial Locations (1)

151-8589

Pfizer, Tokyo

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pfizer

INDUSTRY